Access the world's leading financial data and tools

Subscribe for $2
Overview
Profile

Pacira Biosciences stock

PCRX
US6951271005
A1H68T

Price

20.17
Today +/-
+1.02
Today %
+5.49 %

Pacira Biosciences stock price

%
Weekly
Details

Price

ⓘ

Overview

The Quote Chart provides detailed and dynamic insights into the Pacira Biosciences stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.

Intraday Feature

The intraday feature provides real-time data, allowing investors to view the Pacira Biosciences stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.

Total Return and Relative Price Change

View the total return of the Pacira Biosciences stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.

Interpretation and Investment

Utilize the comprehensive data presented in the Quote Chart to analyze Pacira Biosciences's market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.

Pacira Biosciences Stock Price History

DatePacira Biosciences Price
12/10/202420.17 undefined
12/9/202419.09 undefined
12/6/202419.27 undefined
12/5/202418.67 undefined
12/4/202419.09 undefined
12/3/202416.68 undefined
12/2/202417.81 undefined
11/29/202416.91 undefined
11/27/202416.64 undefined
11/26/202416.78 undefined
11/25/202417.42 undefined
11/22/202417.55 undefined
11/21/202417.40 undefined
11/20/202417.03 undefined
11/19/202416.73 undefined
11/18/202416.64 undefined
11/15/202416.60 undefined
11/14/202416.37 undefined
11/13/202416.58 undefined
11/12/202416.80 undefined
11/11/202417.50 undefined

Pacira Biosciences Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Pacira Biosciences, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Pacira Biosciences from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Pacira Biosciences’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Pacira Biosciences. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Pacira Biosciences’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Pacira Biosciences’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Pacira Biosciences’s growth potential.

Pacira Biosciences Revenue, EBIT and net profit per share

DatePacira Biosciences RevenuePacira Biosciences EBITPacira Biosciences Net Income
2029e501.79 M undefined157.56 M undefined98.9 M undefined
2028e715.92 M undefined291.23 M undefined205.8 M undefined
2027e748.81 M undefined277.77 M undefined193.08 M undefined
2026e807.3 M undefined254.93 M undefined176.84 M undefined
2025e692.78 M undefined201.93 M undefined152.14 M undefined
2024e708.21 M undefined181.52 M undefined145.72 M undefined
2023674.98 M undefined87.32 M undefined41.96 M undefined
2022666.8 M undefined70.9 M undefined15.9 M undefined
2021541.5 M undefined132.8 M undefined42 M undefined
2020429.6 M undefined60.5 M undefined145.5 M undefined
2019421 M undefined35.7 M undefined-11 M undefined
2018337.3 M undefined17.5 M undefined-500,000 undefined
2017286.6 M undefined-20.1 M undefined-42.6 M undefined
2016276.4 M undefined-32 M undefined-37.9 M undefined
2015249 M undefined9.5 M undefined1.9 M undefined
2014197.7 M undefined-5.2 M undefined-13.7 M undefined
201385.6 M undefined-53.3 M undefined-63.9 M undefined
201239.1 M undefined-49.3 M undefined-52.3 M undefined
201115.7 M undefined-36.1 M undefined-43.3 M undefined
201014.6 M undefined-22.7 M undefined-27.1 M undefined
200915 M undefined-28.5 M undefined-31.7 M undefined
200813.9 M undefined-45.4 M undefined-41.9 M undefined
20078.3 M undefined-26 M undefined-36.2 M undefined
200612.4 M undefined-28.2 M undefined-37.3 M undefined
200521 M undefined-28.3 M undefined-34.3 M undefined

Pacira Biosciences Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (M)REVENUE GROWTH (%)GROSS MARGIN (%)GROSS INCOME (M)NET INCOME (M)NET INCOME GROWTH (%)SHARES (M)DOCUMENTS
20052006200720082009201020112012201320142015201620172018201920202021202220232024e2025e2026e2027e2028e2029e
21128131514153985197249276286337421429541666674708692807748715501
--42.86-33.3362.5015.38-6.677.14160.00117.95131.7626.4010.843.6217.8324.931.9026.1123.111.205.04-2.2616.62-7.31-4.41-29.93
23.81-25.00-12.50-23.0813.3314.29-6.6715.3835.2960.9171.0860.1469.2374.1874.5872.7374.1270.1272.7069.2170.8160.7265.5168.5397.80
5-3-1-322-1630120177166198250314312401467490000000
-34-37-36-41-31-27-43-52-63-131-37-420-1114542154114515217619320598
-8.82-2.7013.89-24.39-12.9059.2620.9321.15-79.37-107.69-3,800.0013.51---1,418.18-71.03-64.29173.33253.664.8315.799.666.22-52.20
17.217.217.217.217.217.217.230.333.235.341.337.239.840.941.543.745.646.551.98000000
-------------------------
Details

Keystats

ⓘ

Revenue and Growth

The Pacira Biosciences Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the Pacira Biosciences is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETSCASH BALANCE (M)RECEIVABLES (M)OTHER REC. (M)INVENTORIES (M)OTHER CURRENT LIAB. (M)CURRENT ASSETS (M)TANGIBLE ASSETS (M)LONG-T. INVEST. (M)LONG-T. REC. (M)INTANGIBLE ASSETS (M)GOODWILL (M)OTHER NON-CURRENT ASSETS (M)NON-CURRENT ASSETS (B)TOTAL ASSETS (B)LIABILITIESCOMMON STOCK (k)ADDITIONAL PAID-IN CAPITAL (M)RETAINED EARNINGS (M)OTHER EQUITY (k)UNREAL. GAINS/LOSSES (k)EQUITY (M)LIABILITIES (M)PROVISIONS (M)OTHER SHORT-TERM LIAB. (M)SHORT-TERM DEBTS (M)LONG-TERM DEBT PORTION (M)SHORT-TERM REC. (M)LONG-T. LIAB. (M)DEFERRED TAXES (M)OTHER LIAB. (M)LONG-T. LIABILITIES (M)DEBT (B)TOTAL CAPITAL (B)
2008200920102011201220132014201520162017201820192020202120222023
                               
12.47.126.176.241.172.2156.7159172.6311.3383.5292521.7656.4288.7278.58
2.61.51.22.14.414.622.425.929.931.73847.55396.398.4105.56
0000000000000000
21.71.61.212.115.629.361.631.341.448.658.364.798.696.1104.35
2.42.32.13.13.44.466.19.36.77.910.812.314.815.221.5
19.412.63182.661106.8214.4252.6243.1391.1478408.6651.7866.1498.4509.99
1819.62425.139.148.260.690.3101107108.7142.8211.2264.8254.4234.95
00000024.413.5074.24075.8109.52264.438.46
0000000000000000
13.111.28.95.33.21.20.40.1000104.496.5624540.5483.26
00008.310.323.830.946.755.26299.599.5145.2163.2163.24
0.10.72.60.50.53.42.60.40.60.80.70106.2153.4160.3144.49
0.030.030.040.030.050.060.110.140.150.240.210.420.621.211.181.06
0.050.040.070.110.110.170.330.390.390.630.690.831.272.081.681.57
                               
00000000000000046
85.586.888.5228.5298.3337.6481.3526.7565.2669709.7754873.2942.1924.1976.63
-78.1-109.8-136.9-180.2-232.5-296.4-310.1-308.3-346.2-389.1-388.2-399.4-253.9-211.9-148.8-106.8
000000-100-1000-500-30030000100123
000000000000300100-500124
7.4-23-48.448.365.841.2171.1218.3219279.4321.2354.9619.6730.3774.9870.13
11.874.33.42.63.16.88.77.514.714.412.810.410.515.215.7
1.10.50.62.89.816.625.835.433.239.144.373.376.2126.591.664.52
2.73.65.517.412.341.64.12.21.621.5179.47.38.53
0000099103.110400.30.300000
1.43.35.98.30.810.300000149.6374.733.68.64
1714.416.331.914.2122140149.744.856.360.6107.6253.2521.1147.797.38
3.625.874.720.1260.200108.7276.2290.6306313674.5655.8513.8
0000000000000000
22.426.72413.266.414.919.618.916.516.962.488.5149.3102.693.08
2652.598.733.3326.614.919.6127.6292.7307.5368.4401.5823.8758.4606.87
0.040.070.120.070.050.130.150.170.170.350.370.480.651.340.910.7
0.050.040.070.110.110.170.330.390.390.630.690.831.272.081.681.57
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of Pacira Biosciences provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand Pacira Biosciences's financial health and stability.

Assets

Pacira Biosciences's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that Pacira Biosciences must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of Pacira Biosciences after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into Pacira Biosciences's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (M)DEPRECIATION (M)DEFERRED TAXES (M)CHANGES IN WORKING CAPITAL (M)NON-CASH ITEM (M)PAID INTEREST (M)PAID TAXES (M)NET CASH FLOW FROM OPERATING ACTIVITIES (M)CAPITAL EXPENDITURES (M)CASH FLOW FROM INVESTING ACTIVITIES (M)CASH FLOW FROM OTHER INVESTING ACTIVITIES (M)INTEREST INCOME AND EXPENSES (M)NET DEBT CHANGE (M)NET CHANGE IN EQUITY (M)CASH FLOW FROM FINANCING ACTIVITIES (M)CASH FLOW FROM OTHER FINANCING ACTIVITIES (M)TOTAL DIVIDENDS PAID (M)NET CHANGE IN CASH FLOW (M)FREE CASH FLOW (M)SHARE-BASED COMPENSATION (M)
20072008200920102011201220132014201520162017201820192020202120222023
-36-41-31-27-43-52-63-131-37-420-11145421541
344445510111213131919289175
0000000000000-12610-715
784-20-29-50-2322-2-10-9-33-25-16-45
12030911305471678078104111112110115
1112443543688773327
00000000000002374
-13-29-20-24-31-70-4326283317487077125145154
-3-5-5-6-6-18-12-23-40-24-19-14-10-37-45-30-15
-24-5-5-6-36-29-42-120-19-61-22320-128-277-20-22577
-20000-30-11-30-9721-37-20435-118-23925-19592
00000000000000000
002150008500021500213359-428-181
4540004963311812789104726274
4540215087638911810722493222380-401-183
000038000-1000-6-38-50-5
00000000000000000
75-51920-3622519-211878-5421485-48149
-17-35-26.3-31.7-37.2-88.4-563.6-12.38.8-1.534.460.339.279.8115.2139.49
00000000000000000

Pacira Biosciences stock margins

The Pacira Biosciences margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Pacira Biosciences. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Pacira Biosciences.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Pacira Biosciences's sales revenue. A higher gross margin percentage indicates that the Pacira Biosciences retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Pacira Biosciences's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Pacira Biosciences's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Pacira Biosciences's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Pacira Biosciences. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Pacira Biosciences's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Pacira Biosciences Margin History

Pacira Biosciences Gross marginPacira Biosciences Profit marginPacira Biosciences EBIT marginPacira Biosciences Profit margin
2029e72.64 %31.4 %19.71 %
2028e72.64 %40.68 %28.75 %
2027e72.64 %37.09 %25.79 %
2026e72.64 %31.58 %21.9 %
2025e72.64 %29.15 %21.96 %
2024e72.64 %25.63 %20.58 %
202372.64 %12.94 %6.22 %
202270.11 %10.63 %2.38 %
202174.11 %24.52 %7.76 %
202072.7 %14.08 %33.87 %
201974.66 %8.48 %-2.61 %
201874.24 %5.19 %-0.15 %
201769.33 %-7.01 %-14.86 %
201660.17 %-11.58 %-13.71 %
201571.16 %3.82 %0.76 %
201460.8 %-2.63 %-6.93 %
201335.98 %-62.27 %-74.65 %
201217.65 %-126.09 %-133.76 %
2011-7.01 %-229.94 %-275.8 %
201015.75 %-155.48 %-185.62 %
200918 %-190 %-211.33 %
2008-25.18 %-326.62 %-301.44 %
2007-14.46 %-313.25 %-436.14 %
2006-27.42 %-227.42 %-300.81 %
200527.14 %-134.76 %-163.33 %

Pacira Biosciences Stock Sales Revenue, EBIT, Earnings per Share

The Pacira Biosciences earnings per share therefore indicates how much revenue Pacira Biosciences has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Pacira Biosciences earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Pacira Biosciences's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Pacira Biosciences’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Pacira Biosciences's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Pacira Biosciences Revenue, EBIT and net profit per share

DatePacira Biosciences Sales per SharePacira Biosciences EBIT per sharePacira Biosciences Earnings per Share
2029e10.87 undefined0 undefined2.14 undefined
2028e15.51 undefined0 undefined4.46 undefined
2027e16.22 undefined0 undefined4.18 undefined
2026e17.49 undefined0 undefined3.83 undefined
2025e15 undefined0 undefined3.3 undefined
2024e15.34 undefined0 undefined3.16 undefined
202312.99 undefined1.68 undefined0.81 undefined
202214.34 undefined1.52 undefined0.34 undefined
202111.88 undefined2.91 undefined0.92 undefined
20209.83 undefined1.38 undefined3.33 undefined
201910.14 undefined0.86 undefined-0.27 undefined
20188.25 undefined0.43 undefined-0.01 undefined
20177.2 undefined-0.51 undefined-1.07 undefined
20167.43 undefined-0.86 undefined-1.02 undefined
20156.03 undefined0.23 undefined0.05 undefined
20145.6 undefined-0.15 undefined-0.39 undefined
20132.58 undefined-1.61 undefined-1.92 undefined
20121.29 undefined-1.63 undefined-1.73 undefined
20110.91 undefined-2.1 undefined-2.52 undefined
20100.85 undefined-1.32 undefined-1.58 undefined
20090.87 undefined-1.66 undefined-1.84 undefined
20080.81 undefined-2.64 undefined-2.44 undefined
20070.48 undefined-1.51 undefined-2.1 undefined
20060.72 undefined-1.64 undefined-2.17 undefined
20051.22 undefined-1.65 undefined-1.99 undefined

Pacira Biosciences business model

Pacira Biosciences Inc. is an international pharmaceutical company specializing in the development and manufacture of innovative drugs for use in anesthesia, pain management, and oncology. The company was founded in 2007 and is headquartered in Parsippany, New Jersey. Pacira Biosciences' success story began with the development of EXPAREL, a long-acting painkiller based on liposome technology. EXPAREL was the first product approved by the US Food and Drug Administration (FDA) for local infiltration to relieve pain after surgery. Since then, the company has expanded its portfolio and now offers products for use in oncology and other areas of medicine. Pacira Biosciences' business model is based on the manufacture and sale of high-quality, innovative drugs both in the US and internationally. Product development is done in close collaboration with doctors and patients to ensure that patient needs are met and medical requirements are fulfilled. The company operates in three main divisions: anesthesia, pain management, and oncology. In the anesthesia division, Pacira Biosciences offers the product EXPAREL, which is used for local infiltration into the surgical wound to relieve pain after surgery. EXPAREL is a liposomal, slow-release painkiller that enables patients to recover without pain and minimizes the risk of opioid dependence. In the pain management division, Pacira Biosciences has developed the products bupivacaine and meloxicam, which are used in the treatment of acute and chronic pain. These products provide a safe and effective alternative to opioids for pain management. In the oncology division, the company has introduced the product ONIVYDE, which is used for the treatment of patients with metastatic pancreatic cancer. ONIVYDE was developed in collaboration with the FDA and has proven to be effective in combating cancer. In addition to offering products, Pacira Biosciences works closely with doctors, hospitals, and government agencies to ensure that the products are used safely and effectively. The company also conducts extensive research and development activities to develop new products and improve existing ones. In conclusion, Pacira Biosciences Inc. is a leading international company specializing in innovative pharmaceuticals in the fields of anesthesia, pain management, and oncology. The company is actively working on developing new innovative products and offering doctors and patients a safe and effective alternative to traditional pain medications. With its strong commitment to the healthcare industry, Expard will continue to advance the development of new and therapeutic agents to better assist patients. Answer: Pacira Biosciences Inc. is an international pharmaceutical company specializing in the development and manufacture of innovative drugs for anesthesia, pain management, and oncology. They are known for their product EXPAREL, a long-acting painkiller approved by the FDA for local infiltration after surgery. The company operates in three divisions and works closely with healthcare professionals and government agencies to ensure safe and effective use of their products. They are committed to advancing healthcare through research and development. Pacira Biosciences is one of the most popular companies on Eulerpool.com.

Pacira Biosciences SWOT Analysis

Strengths

  • Pacira Biosciences is a well-established pharmaceutical company with a strong presence in the market.
  • The company has a diverse and innovative product portfolio, including its flagship product, EXPAREL®, which is widely recognized and trusted by healthcare professionals.
  • Pacira Biosciences has a robust research and development strategy, allowing for continuous expansion and improvement of its product offerings.

Weaknesses

  • The company relies heavily on the success of EXPAREL®, which exposes it to significant risk if the product faces any setbacks or stiff competition.
  • Pacira Biosciences has limited geographical reach, primarily operating within the United States, which restricts its global market potential.
  • The company may struggle to maintain profitability due to the high costs associated with research, development, and marketing of its products.

Opportunities

  • Pacira Biosciences can explore international expansion to tap into new markets and diversify its revenue streams.
  • The increasing focus on personalized medicine and the growing demand for non-opioid pain management solutions present significant opportunities for Pacira Biosciences to expand its product offerings.
  • Collaboration with healthcare providers, insurance companies, and other stakeholders can enhance market penetration and promote the adoption of Pacira Biosciences' products.

Threats

  • The pharmaceutical industry is highly competitive, with the presence of major players and constant technological advancements, posing a threat to Pacira Biosciences' market share.
  • Regulatory approval processes and potential changes in healthcare policies can impact the availability and reimbursement of Pacira Biosciences' products.
  • Economic downturns and fluctuations in healthcare spending can lead to reduced demand for pharmaceutical products, including Pacira Biosciences' offerings.

Pacira Biosciences Revenue by Segment

  • Max

Details

Revenue by Segment

ⓘ

Overview of Revenue by Segment

The chart visualizes revenues by segments and provides a clear overview of the revenue distribution. Each segment is clearly marked to facilitate comparisons of revenues.

Interpretation and Use

The chart enables quick identification of the highest-revenue segments, which is helpful in strategic decision-making. It supports the analysis of growth potentials and targeted resource allocation.

Investment Strategy

An investment strategy determines how capital is deliberately invested into various asset classes to maximize returns. It is based on risk tolerance, investment objectives, and a long-term plan.

Pacira Biosciences Revenue by Segment

Segmente202320222021202020192018
Net product sales672.25 M USD664.15 M USD----
Royalty revenue2.73 M USD2.67 M USD----
Collaborative licensing and milestone revenue------

  • Max

Details

Revenue by Segment

ⓘ

Overview of Revenue by Segment

The chart visualizes revenues by segments and provides a clear overview of the revenue distribution. Each segment is clearly marked to facilitate comparisons of revenues.

Interpretation and Use

The chart enables quick identification of the highest-revenue segments, which is helpful in strategic decision-making. It supports the analysis of growth potentials and targeted resource allocation.

Investment Strategy

An investment strategy determines how capital is deliberately invested into various asset classes to maximize returns. It is based on risk tolerance, investment objectives, and a long-term plan.

Pacira Biosciences Revenue by Segment

Segmente202320222021202020192018
EXPAREL538.12 M USD536.9 M USD----
ZILRETTA111.1 M USD105.52 M USD----
iovera°19.69 M USD15.26 M USD----
Bupivacaine liposome injectable suspension3.34 M USD6.48 M USD----

  • 3 years

  • 5 years

  • Max

Details

Revenue by Segment

ⓘ

Overview of Revenue by Segment

The chart visualizes revenues by segments and provides a clear overview of the revenue distribution. Each segment is clearly marked to facilitate comparisons of revenues.

Interpretation and Use

The chart enables quick identification of the highest-revenue segments, which is helpful in strategic decision-making. It supports the analysis of growth potentials and targeted resource allocation.

Investment Strategy

An investment strategy determines how capital is deliberately invested into various asset classes to maximize returns. It is based on risk tolerance, investment objectives, and a long-term plan.

Pacira Biosciences Revenue by Segment

Segmente202320222021202020192018
EXPAREL--506.52 M USD--331.11 M USD
iovera°--16.16 M USD---
ZILRETTA--12.68 M USD---
Bupivacaine liposome injectable suspension--3.61 M USD---
Other product sales-----1.32 M USD

  • 3 years

  • Max

Details

Revenue by Segment

ⓘ

Overview of Revenue by Segment

The chart visualizes revenues by segments and provides a clear overview of the revenue distribution. Each segment is clearly marked to facilitate comparisons of revenues.

Interpretation and Use

The chart enables quick identification of the highest-revenue segments, which is helpful in strategic decision-making. It supports the analysis of growth potentials and targeted resource allocation.

Investment Strategy

An investment strategy determines how capital is deliberately invested into various asset classes to maximize returns. It is based on risk tolerance, investment objectives, and a long-term plan.

Pacira Biosciences Revenue by Segment

Segmente202320222021202020192018
EXPAREL/bupivacaine liposome injectable suspension---417.8 M USD411.03 M USD-
iovera°---8.82 M USD--
iovera° [Member]----7.9 M USD-
DepoCyte------
LIMITED TIME OFFER

The World’s Best Investors Are On Eulerpool

Subscribe for $2

Pacira Biosciences Eulerpool Fair Value

Details

Fair Value

ⓘ

Understanding Fair Value

The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.

Income-Based Fair Value

This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.

Example 2022

Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)

Revenue-Based Fair Value

It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.

Example 2022

Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)

Dividend-Based Fair Value

This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.

Example 2022

Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)

Expectations and Forecasts

Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.

Comparative Analysis

Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.

Pacira Biosciences historical P/E ratio, EBIT multiple, and P/S ratio

LIMITED TIME OFFER

The World’s Best Investors Are On Eulerpool

Subscribe for $2

Pacira Biosciences shares outstanding

The number of shares was Pacira Biosciences in 2023 — This indicates how many shares 51.979 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Pacira Biosciences earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Pacira Biosciences's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Pacira Biosciences’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Pacira Biosciences's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

LIMITED TIME OFFER

The World’s Best Investors Are On Eulerpool

Subscribe for $2
Unfortunately, there are currently no price targets and forecasts available for Pacira Biosciences.

Pacira Biosciences latest earnings and earnings surprises

DateEPS EstimateEPS ActualQuarterly report
9/30/20240.72 0.79  (9.92 %)2024 Q3
6/30/20240.71 0.89  (24.81 %)2024 Q2
3/31/20240.64 0.62  (-2.59 %)2024 Q1
12/31/20230.9 0.89  (-1.22 %)2023 Q4
9/30/20230.8 0.72  (-9.97 %)2023 Q3
6/30/20230.77 0.78  (0.88 %)2023 Q2
3/31/20230.63 0.53  (-15.78 %)2023 Q1
12/31/20220.85 0.8  (-5.48 %)2022 Q4
9/30/20220.78 0.64  (-17.88 %)2022 Q3
6/30/20220.87 0.51  (-41.29 %)2022 Q2
1
2
3
4
5
...
6

Eulerpool ESG Scorecard© for the Pacira Biosciences stock

Eulerpool World ESG Rating (EESG©)

66/ 100

🌱 Environment

31

👫 Social

94

🏛️ Governance

72

Environment

Scope 1 - Direct Emissions
Scope 2 - Indirect emissions from purchased energy
Scope 3 - Indirect emissions within the value chain
Total CO₂ emissions
CO₂ reduction strategy
Coal energy
Nuclear power
Animal experiments
Fur & Leather
Pesticides
Palm Oil
Tobacco
Genetically modified organisms
Climate concept
Sustainable forestry
Recycling regulations
Environmentally friendly packaging
Hazardous substances
Fuel consumption and efficiency
Water consumption and efficiency

Social

Percentage of female employees43
Percentage of women in management
Percentage of Asian employees
Share of Asian management
Percentage of Hispanic/Latino employees
Hispano/Latino Management share
Percentage of Black employees
Black Management Share
Percentage of white employees
White Management Share
Adult content
Alcohol
Weapons
Firearms
Gambling
Military contracts
Human rights concept
Privacy concept
Occupational health and safety
Catholic

Governance (Corporate Governance)

Environmental reporting
Stakeholder Engagement
Call Back Policies
Antitrust law

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

Pacira Biosciences shareholders

%
Name
Stocks
Change
Date
15.34064 % BlackRock Institutional Trust Company, N.A.7,082,772-13,2696/30/2024
10.99374 % The Vanguard Group, Inc.5,075,809-28,5536/30/2024
4.68440 % Pacer Advisors, Inc.2,162,787590,0826/30/2024
4.47519 % Renaissance Technologies LLC2,066,197184,0006/30/2024
4.12357 % State Street Global Advisors (US)1,903,8502386/30/2024
3.97850 % Frontier Capital Management Company, LLC1,836,873-77,4706/30/2024
3.95942 % Dimensional Fund Advisors, L.P.1,828,065198,9366/30/2024
3.39401 % Macquarie Investment Management1,567,0135,9746/30/2024
2.35933 % Geode Capital Management, L.L.C.1,089,30452,6236/30/2024
2.16756 % DOMA Perpetual Capital Management, LLC1,000,761418,3216/30/2024
1
2
3
4
5
...
10

Pacira Biosciences Executives and Management Board

Mr. David Stack

(72)
Pacira Biosciences Chairman of the Board, Chief Executive Officer (since 2007)
Compensation 6.85 M

Mr. Dennis Mcloughlin

(57)
Pacira Biosciences Chief Customer Officer
Compensation 2.53 M

Dr. Roy Winston

(62)
Pacira Biosciences Chief Medical Officer and Orthopedic Franchise
Compensation 2.48 M

Mr. Daryl Gaugler

(61)
Pacira Biosciences Chief Operating Officer
Compensation 2.29 M

Dr. Jonathan Slonin

(48)
Pacira Biosciences Chief Clinical Officer
Compensation 2.12 M
1
2
3
4
...
5

Pacira Biosciences Supply Chain

NameRelationshipTwo-week correlationOne-month correlationThree-Month CorrelationSix-Month CorrelationOne Year CorrelationTwo-Year Correlation
Elanco Animal Health Stock
Elanco Animal Health
SupplierCustomer0,700,850,80-0,10-0,58-0,17
Xenon Pharmaceuticals Stock
Xenon Pharmaceuticals
SupplierCustomer0,640,380,720,650,380,21
Thermo Fisher Scientific Stock
Thermo Fisher Scientific
SupplierCustomer0,550,540,67-0,38-0,17-0,04
Carlisle Cos Stock
Carlisle Cos
SupplierCustomer0,520,56-0,110,280,520,15
Omnicom Stock
Omnicom
SupplierCustomer0,510,380,580,590,650,37
McKesson Stock
McKesson
SupplierCustomer0,24-0,74-0,260,670,790,41
Cardinal Health Stock
Cardinal Health
SupplierCustomer0,200,720,390,770,670,52
AmerisourceBergen Stock
AmerisourceBergen
SupplierCustomer0,19-0,290,220,780,840,39
1

Most common questions regarding Pacira Biosciences

What values and corporate philosophy does Pacira Biosciences represent?

Pacira Biosciences Inc represents a commitment to improving patient outcomes and transforming the surgical experience. Their corporate philosophy is centered around finding innovative solutions for postsurgical pain management and reducing opioid use. With a focus on responsible drug development, Pacira prioritizes patient safety, clinical evidence, and collaboration with healthcare professionals. The company strives to provide patients with non-opioid alternatives for pain control, aiming to enhance recovery and minimize the risk of opioid-related complications. Pacira Biosciences Inc emphasizes ethical practices and dedicated research to address unmet medical needs in surgical care.

In which countries and regions is Pacira Biosciences primarily present?

Pacira Biosciences Inc is primarily present in various countries and regions worldwide. The company has established its presence in the United States, enabling it to cater to the North American market effectively. Additionally, Pacira Biosciences Inc has expanded its reach globally, with a strong presence in Europe, Asia, and other international regions. By strategically establishing its presence in multiple countries and regions, Pacira Biosciences Inc aims to provide its innovative healthcare solutions and products to a diverse range of patients and healthcare providers across the globe.

What significant milestones has the company Pacira Biosciences achieved?

Pacira Biosciences Inc, a renowned pharmaceutical company, has achieved several significant milestones. Notably, the company successfully developed and commercialized Exparel, a cutting-edge non-opioid pain management medication widely used in surgical procedures. Pacira Biosciences Inc also made significant progress in expanding its product pipeline by successfully launching iovera, a minimally invasive treatment option for managing pain. Additionally, the company's continuous commitment to research and development has led to numerous innovative drug formulations and collaborations with global healthcare institutions. Through its steadfast dedication to improving patient outcomes, Pacira Biosciences Inc has cemented its position as a leading player in the pharmaceutical industry.

What is the history and background of the company Pacira Biosciences?

Pacira Biosciences Inc is a leading pharmaceutical company specializing in non-opioid pain management and regenerative health solutions. Established in 2006, the company is headquartered in Parsippany, New Jersey. Pacira Biosciences focuses on developing innovative therapies for acute pain management and surgical applications. With a dedication to improving patient outcomes and reducing opioid dependence, they have introduced groundbreaking products like EXPAREL®, a long-acting local analgesic. Pacira Biosciences has transformed pain management practices across various surgical specialties, providing patients with effective alternatives to opioids. The company's commitment to research, development, and pioneering advancements makes Pacira Biosciences Inc a trusted name in the healthcare industry.

Who are the main competitors of Pacira Biosciences in the market?

The main competitors of Pacira Biosciences Inc in the market include Johnson & Johnson, Pfizer Inc, and Teva Pharmaceutical Industries Ltd. These companies operate in the pharmaceutical industry and offer similar products and services. Pacira Biosciences Inc faces competition in its primary focus area of developing and commercializing innovative pharmaceutical products for post-surgical pain management. Competitors like Johnson & Johnson, Pfizer Inc, and Teva Pharmaceutical Industries Ltd constantly strive to capture market share by introducing new products and technologies. However, Pacira Biosciences Inc has successfully positioned itself as a competitive player in the market through its strong product portfolio and focus on research and development efforts.

In which industries is Pacira Biosciences primarily active?

Pacira Biosciences Inc primarily operates in the pharmaceutical industry.

What is the business model of Pacira Biosciences?

The business model of Pacira Biosciences Inc is focused on developing and commercializing innovative pharmaceutical products for use in hospitals and ambulatory surgery centers. The company specializes in creating and delivering non-opioid pain management therapies. Pacira Biosciences Inc's flagship product, EXPAREL®, is a long-acting local analgesic that provides extended pain relief after surgery. With a strong emphasis on research and development, Pacira Biosciences Inc aims to improve patient outcomes and reduce opioid consumption by providing alternative pain management solutions. This commitment to innovation and patient care drives the company's success in the healthcare industry.

What is the P/E ratio of Pacira Biosciences 2024?

The Pacira Biosciences P/E ratio is 7.19.

What is the P/S ratio of Pacira Biosciences 2024?

The Pacira Biosciences P/S ratio is 1.48.

What is the Quality Investing of Pacira Biosciences?

The Quality Investing for Pacira Biosciences is 4/10.

What is the revenue of Pacira Biosciences 2024?

The expected Pacira Biosciences revenue is 708.21 M USD.

How high is the profit of Pacira Biosciences 2024?

The expected Pacira Biosciences profit is 145.72 M USD.

What is the business model of Pacira Biosciences

Pacira Biosciences Inc is a global pharmaceutical company specializing in the development, manufacturing, and marketing of innovative pain relief medications. The company was founded in 1999 and is headquartered in Parsippany, New Jersey, USA. It is listed on the NASDAQ stock exchange and employs over 1,300 people worldwide. The company's business model is based on the research and development of medications focused on pain treatment. Pacira Biosciences focuses on developing medications using its proprietary liposome technology, which helps to effectively and prolong the action of active substances in the body, thereby improving pain relief. Pacira Biosciences Inc's products mainly include Exparel (Bupivacaine liposome injectable suspension), a long-acting pain medication used for postoperative pain management. Exparel is used in orthopedics, gynecology, plastic surgery, general surgery, and other areas where pain relief is needed during the recovery phase after surgery. In addition to Exparel, Pacira Biosciences also has a pipeline of development projects for new medications, including DepoCyt (Cytarabine liposome injection), a medication for certain types of cancer. The company is divided into three business segments: Products, Research and Development, and Corporate. The Products segment is responsible for marketing and sales of Exparel in the US and Europe. The Research and Development segment is responsible for the development of new medications and pain therapy technologies. The Corporate segment coordinates general operational matters, finances, human resources, legal and compliance issues, as well as marketing and communication activities for the company. Overall, Pacira Biosciences Inc's business model focuses on developing and marketing innovative and effective pain medications based on its liposome technology. It primarily addresses the needs of patients and doctors for improved pain relief in postoperative pain management.

What is the Pacira Biosciences dividend?

Pacira Biosciences pays a dividend of 0 USD distributed over payouts per year.

How often does Pacira Biosciences pay dividends?

The dividend cannot currently be calculated for Pacira Biosciences or the company does not pay out a dividend.

What is the Pacira Biosciences ISIN?

The ISIN of Pacira Biosciences is US6951271005.

What is the Pacira Biosciences WKN?

The WKN of Pacira Biosciences is A1H68T.

What is the Pacira Biosciences ticker?

The ticker of Pacira Biosciences is PCRX.

How much dividend does Pacira Biosciences pay?

Over the past 12 months, Pacira Biosciences paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Pacira Biosciences is expected to pay a dividend of 0 USD.

What is the dividend yield of Pacira Biosciences?

The current dividend yield of Pacira Biosciences is .

When does Pacira Biosciences pay dividends?

Pacira Biosciences pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Pacira Biosciences?

Pacira Biosciences paid dividends every year for the past 0 years.

What is the dividend of Pacira Biosciences?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Pacira Biosciences located?

Pacira Biosciences is assigned to the 'Health' sector.

Wann musste ich die Aktien von Pacira Biosciences kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Pacira Biosciences from 12/10/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 12/10/2024.

When did Pacira Biosciences pay the last dividend?

The last dividend was paid out on 12/10/2024.

What was the dividend of Pacira Biosciences in the year 2023?

In the year 2023, Pacira Biosciences distributed 0 USD as dividends.

In which currency does Pacira Biosciences pay out the dividend?

The dividends of Pacira Biosciences are distributed in USD.

All fundamentals about Pacira Biosciences

Our stock analysis for Pacira Biosciences Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Pacira Biosciences Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.